BR112014023092A8 - Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit - Google Patents

Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit

Info

Publication number
BR112014023092A8
BR112014023092A8 BR112014023092A BR112014023092A BR112014023092A8 BR 112014023092 A8 BR112014023092 A8 BR 112014023092A8 BR 112014023092 A BR112014023092 A BR 112014023092A BR 112014023092 A BR112014023092 A BR 112014023092A BR 112014023092 A8 BR112014023092 A8 BR 112014023092A8
Authority
BR
Brazil
Prior art keywords
hpv
immunogenic composition
disease
infection
kit
Prior art date
Application number
BR112014023092A
Other languages
English (en)
Other versions
BR112014023092A2 (pt
Inventor
Desiree Alberte Colau Brigitte
Giannini Sandra
Lockman Laurence
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BR112014023092A2 publication Critical patent/BR112014023092A2/pt
Publication of BR112014023092A8 publication Critical patent/BR112014023092A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

COMPOSIÇÃO IMUNOGÊNICA, MÉTODO PARA A PREVENÇÃO DE INFECÇÃO OU DOENÇA POR HPV EM UM INDIVÍDUO, E, KIT. A revelação fornece composições imunogênicas compreendendo VLPs do HPV de um ou mais tipos de HPV em combinação com um adjuvante compreendendo um agonista TLR para uso em um método para a prevenção de infecção ou doença por HPV em um indivíduo, em que uma primeira dose da composição imunogênica compreendendo VLPs do HPV e um agonista TLR é administrada, seguida por uma segunda dose de uma composição imunogênica compreendendo VLPs do HPV de um ou mais tipos de HPV, mas que não compreende um agonista TLR.
BR112014023092A 2012-03-18 2013-03-18 Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit BR112014023092A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261612345P 2012-03-18 2012-03-18
PCT/EP2013/055582 WO2013139744A1 (en) 2012-03-18 2013-03-18 Method of vaccination against human papillomavirus

Publications (2)

Publication Number Publication Date
BR112014023092A2 BR112014023092A2 (pt) 2017-06-20
BR112014023092A8 true BR112014023092A8 (pt) 2017-07-25

Family

ID=47913410

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014023092A BR112014023092A8 (pt) 2012-03-18 2013-03-18 Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit

Country Status (7)

Country Link
US (1) US20150110824A1 (pt)
EP (1) EP2827891A1 (pt)
JP (1) JP2015514696A (pt)
CN (1) CN104203270A (pt)
BR (1) BR112014023092A8 (pt)
CA (1) CA2866582A1 (pt)
WO (1) WO2013139744A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
AU2015335652B2 (en) 2014-10-24 2020-07-02 Hpvvax, Llc. Cancer and skin lesion treatment
WO2017147475A1 (en) * 2016-02-27 2017-08-31 Hpvvax, Llc Method and composition for treating cancer or skin lesion using a vaccine
EP4112638A1 (en) * 2016-05-16 2023-01-04 Access to Advanced Health Institute Formulation containing tlr agonist and methods of use

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP1298211B1 (en) 1991-07-19 2006-07-12 The University Of Queensland Polynucleotide segment of HPV16 Genome
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
PT1618888E (pt) 1993-03-09 2011-04-08 Univ Rochester Produção de proteína da cápside de vírus de papiloma humano e partículas semelhantes a vírus
CN1087176C (zh) 1993-03-23 2002-07-10 史密斯克莱·比奇曼生物公司 含有3－o脱酰基单磷酰脂a的疫苗制剂
WO1995014026A1 (en) 1993-11-17 1995-05-26 Laboratoires Om S.A. Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
ATE325875T1 (de) 1994-10-07 2006-06-15 Univ Loyola Chicago Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
IL117459A (en) 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
EP1700911B1 (en) 1997-09-05 2016-04-06 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs)
US6060324A (en) 1997-11-12 2000-05-09 Phytochem Technologies, Inc. Fluorometric assay composition for measurement of antioxidant activity
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
SK18602000A3 (sk) 1998-06-08 2001-07-10 Sca Emballage France Obal umožňujúci rýchle vyrovnanie
HUP0102475A3 (en) 1998-06-30 2001-12-28 Om Pharma Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same
EP2266604A3 (en) 1998-10-16 2011-05-11 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
JP4331944B2 (ja) 2001-04-17 2009-09-16 大日本住友製薬株式会社 新規アデニン誘導体
JP2005513021A (ja) 2001-11-16 2005-05-12 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトール様受容体経路に関する方法および組成物
CN1234851C (zh) * 2003-01-30 2006-01-04 上海天甲生物医药有限公司 抗人乳头状瘤病毒疫苗
JP2012530505A (ja) 2009-06-25 2012-12-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規ヒトパピローマウイルス（ｈｐｖ）タンパク質構築物及びｈｐｖ疾患の予防におけるそれらの使用

Also Published As

Publication number Publication date
JP2015514696A (ja) 2015-05-21
BR112014023092A2 (pt) 2017-06-20
US20150110824A1 (en) 2015-04-23
WO2013139744A1 (en) 2013-09-26
CN104203270A (zh) 2014-12-10
EP2827891A1 (en) 2015-01-28
CA2866582A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
CL2015000331A1 (es) Compuestos derivados de piridazina 1,4-disustitutidos; composicion y combinacion farmaceutica que los comprende y uso en el tratamiento de la atrofia muscular espinal.
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
BR112015010059A2 (pt) terapia adjuvante com inibidor da quinase da família tec
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
BR112015027704A2 (pt) Composto, uso do mesmo e composição farmacêutica antibacteriana
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
BRPI1013780A2 (pt) composições para imunização contra staphylococcus aureus.
CL2012002606A1 (es) Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
BR212012031500U2 (pt) composições sólidas
BR112012004806B8 (pt) composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
GT201400111A (es) Triazolopiridinas sustituidas
CL2012002551A1 (es) Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor.
BR112015004515A2 (pt) composição imunogênica
BR112015015870A8 (pt) composição farmacêutica, e, uso de uma composição farmacêutica
BR112017000519A2 (pt) "composição imunogênica, e, método para proteger um mamífero contra uma infecção meningocócica"
CO6551750A2 (es) Vacuna del virus del dengue inactivado que incluye un adyuvante sin aluminio
BR112015017241A8 (pt) composto, composição farmacêutica, uso do composto e da composição farmacêutica e kit
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]